Angioplasty versus surgery in patients with critical lower limb ischemia

Original title: Comparative effectiveness of endovascular andsurgical revascularization for patients with peripheralartery disease and critical limb ischemia: Systematicreview of revascularization in critical limb ischemia. Reference: W Schuyler Jones, et al. (Am Heart J 2014; 167:167:489-498.e7)

Lower limbs critical ischemia is the most severe condition of PAD. The morbidity, mortality and costs related thereto are well documented; however, the method of choice to prevent amputation, death and preserve functional capacity is not yet defined. 

This paper reviewed the relevant studies published from 1995 to 2012, in which endovascular technique was compared with surgery regarding death, cardiovascular events, amputation, quality of life, patency of the case treated and reintervention. Both techniques in 23 works were compared totalling 12,779 patients with critical lower limb ischemia. One of the studies was randomized, and 22 were observational. The average age of the patients ranged between 61 and 83 years, the number of patients evaluated ranged from 73 to 4,929, and the length of study was 30 days to 60 months. The quality of the studies evaluated was also a variable.

In terms of all-cause mortality, no significant superiority of the endovascular procedure at 6 months was found, but this disappeared after two years, being the same in both procedures. No difference was found between the procedures in assessing long-term amputation. Nine studies assessed vessel patency, being higher in the endovascular procedure. One study evaluated the time to healing chronic wounds, resulting this lower in the surgical procedure. The research also assessed other variables such as age, anatomical factors, tissue loss and technique used, with varying results without statistical significance. None of the studies considered subgroups by sex, race, smoking or the presence of renal insufficiency.

Conclusion

The conclusion reached in the present meta-analysis is that the evidence available at the time for the treatment of critical lower limb ischemia is limited since it is based on few studies, most of them non-randomized, not superiority lies between angioplasty and surgery.

Editorial comment

The only important randomized study is the BASIL, which recruited patients more than 10 years ago to compare both techniques, however, in the endovascular branch, current technologies in terms of stents, balloons, etc., were not used. Even so, based on this information, in 2011 the existing guidelines were updated, indicating that both procedures were similar. Randomized studies are needed to compare both techniques using current technologies.

Courtesy of Alfonso Francisco Balaguer Quiroga MD
Interventional Cardiologist.
International Clinic. Lima, Peru.

Dr. Alfonso Francisco Balaguer Quiroga

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...